

AMENDMENTS TO THE CLAIMS

Claims 18, 19, and 25-59 are pending.

Claims 39, 40, 45, 46, 52 and 53 are being canceled, and claims 18, 38, 44 and 50 are being amended. After the amendments, claims 18, 19, 25-38, 41-44, 47-51 and 54-59 will be pending.

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1.-17. (Canceled)

18. (Currently amended) A method of preparing a cellular composition for transplantation into a recipient, comprising the steps of:

- (a) selecting a cellular composition for transplantation; and
- (b) contacting the composition with a reovirus *ex vivo* to result in oncolysis of ras-mediated neoplastic cells;

~~wherein said transplantation is autologous.~~

19. (Previously presented) A method of preparing a cellular composition for transplantation into a recipient, comprising the steps of:

- (a) selecting a cellular composition for transplantation;
- (b) contacting the composition with a reovirus *ex vivo* to result in oncolysis of ras-mediated neoplastic cells; and
- (c) administering to the transplant recipient at least one substance selected from the group consisting of anti-reovirus antibodies and immune system stimulating agents.

20.-24. (Canceled)

25. (Previously presented) The method of claim 18 wherein the reovirus is a mammalian reovirus.
26. (Previously presented) The method of claim 18 wherein the reovirus is an avian reovirus.
27. (Previously presented) The method of claim 25 wherein the mammalian reovirus is a human reovirus.
28. (Previously presented) The method of claim 25 wherein the mammalian reovirus is serotype 3 virus.
29. (Previously presented) The method of claim 28 wherein the serotype 3 virus is the Dearing strain.
30. (Previously presented) The method of claim 18 further comprising the step of freezing and storing the reovirus-treated composition in a solution containing DMSO.
31. (Previously presented) The method of claim 19 wherein the transplantation is autologous.
32. (Previously presented) The method of claim 19 wherein the reovirus is a mammalian reovirus.
33. (Previously presented) The method of claim 19 wherein the reovirus is an avian reovirus.
34. (Previously presented) The method of claim 32 wherein the mammalian reovirus is a human reovirus.

35. (Previously presented) The method of claim 32 wherein the mammalian reovirus is serotype 3 virus.

36. (Previously presented) The method of claim 35 wherein the serotype 3 virus is the Dearing strain.

37. (Previously presented) The method of claim 31 further comprising the step of freezing and storing the reovirus-treated composition in a solution containing DMSO.

38. (Currently amended) The method of claim 18 wherein the cellular composition comprises hematopoietic stem cells that have been harvested from blood.

39.-40. (Canceled)

41. (Previously presented) The method of claim 18 wherein the cellular composition comprises a tissue, an organ or any portion of a tissue or an organ.

42. (Previously presented) The method of claim 41 wherein the tissue or organ is selected from the group consisting of liver, kidney, heart, cornea, skin, lung, pancreatic islet cells, and whole blood.

43. (Previously presented) The method of claim 18 wherein the cellular composition comprises cultured cells, semen or eggs.

44. (Currently amended) The method of claim 19 wherein the cellular composition comprises hematopoietic stem cells that have been harvested from blood.

45.-46. (Canceled)

47. (Previously presented) The method of claim 19 wherein the cellular composition comprises a tissue, an organ or any portion of a tissue or an organ.
48. (Previously presented) The method of claim 47 wherein the tissue or organ is selected from the group consisting of liver, kidney, heart, cornea, skin, lung, pancreatic islet cells, and whole blood.
49. (Previously presented) The method of claim 19 wherein the cellular composition comprises cultured cells, semen or eggs.
50. (Currently amended) A method of preparing a cellular composition that comprises hematopoietic stem cells harvested from blood for transplantation into a recipient, comprising contacting the cellular composition with a reovirus *ex vivo* to result in oncolysis of ras-mediated neoplastic cells ~~under conditions that does not alter~~ without altering the ability of the hematopoietic cells to differentiate into each and every hematopoietic lineage.
51. (Previously presented) The method of claim 50 wherein the transplantation is autologous.
- 52.-53. (Canceled)
54. (Previously presented) The method of claim 50 further comprising the step of removing the reovirus from the reovirus-treated composition.
55. (Previously presented) The method of claim 54 wherein the reovirus is removed by freezing and storing the reovirus-treated composition in a solution containing DMSO.
56. (Previously presented) The method of claim 50 wherein the reovirus is a mammalian reovirus or an avian reovirus.

57. (Previously presented) The method of claim 50 wherein the reovirus is a human reovirus.
58. (Previously presented) The method of claim 50 wherein the reovirus is serotype 3 virus.
59. (Previously presented) The method of claim 50 wherein the reovirus is the Dearing strain.